. 2005 Jan 28;11(4):538–544. doi: 10.3748/wjg.v11.i4.538

Table 6.

Pancreatic dry weight/wet weight ratio and serum amylase (effect of PACAP receptor antagonists) (mean±SE).

Group	Dry weight/wet weight ratio (%)	Serum amylase (IU/L)
Normal control	29.21±5.657	520.8±163.27
Caerulein-induced pancreatitis	21.83±3.013^a	3699.33±3826.56^a
Sodium taurocholate-induced pancreatitis	17.52±1.505^a	3690.87±2277.99^a
10 μg PACAP6-27	25.25±2.286^a	1464.33±265.6^a
100 μg PACAP6-27	26.21±2.577	1692.17±312.18^a
Caerulein+10 μg PACAP6-27	22.75±3.523^a	2484.33±1459.64^a
Caerulein+100 μg PACAP6-27	21.4±4.152^a	6485.5±3352.84^a
Sodium taurocholate+10 μg PACAP6-27	20.81±3.94^a	5026.83±3697.35^a
Sodium taurocholate+100 μg PACAP6-27	17.99±3.594^a	7667.67±4270.93^a
10 μg (4-Cl-D-Phe6, Leu17) VIP	25.61±2.389^a	1 337.17±314.02^a
100 μg (4-Cl-D-Phe6, Leu17) VIP	26.77±1.377	1781±527.65^a
Caerulein+10 μg (4-Cl-D-Phe6, Leu17) VIP	24.33±0.939^a	2875.33±582.98^a
Caerulein+100 μg (4-Cl-D-Phe6, Leu17) VIP	22.36±2.13^a	8307.83±2003.41^a
Sodium taurocholate+10 μg (4-Cl-D-Phe6, Leu17) VIP	16.89±1.18^a	4684.33±993.55^a
Sodium taurocholate+100 μg (4-Cl-D-Phe6, Leu17) VIP	18.71±4.048^a	7264.67±2834.91^a

P<0.05 vs normal control.